# A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

> **NCT02008227** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1225 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02008227
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-11
- **Primary completion:** 2016-07-07
- **Final completion:** 2019-01-09
- **Target enrollment:** 1225 (ACTUAL)
- **Last updated:** 2019-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008227, "A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02008227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*